Small Molecule Drug Product CDMOs

Padagis LLC

United States

Padagis LLC is a U.S.-based generic pharmaceutical company specializing in development and manufacturing of extended topical and specialty pharmaceutical products. Product portfolio includes prescription creams, ointments, gels, foams, sprays, patches, nasal treatments, and suppositories, with a focus on Paragraph IV generic products. Also manufactures naloxone nasal spray (awarded New York State Department of Health contract in 2025). Over 1,300 employees. Offers contract manufacturing, licensing, and joint venture partnerships.

Panacea Biotec Ltd.

India

Panacea Biotec Ltd. is an Indian biotechnology company engaged in research, development, manufacturing, and marketing of branded pharmaceuticals and vaccines. The company has a USFDA-approved manufacturing facility at Baddi and WHO prequalified operations. Panacea Biotec also offers contract manufacturing services for pharmaceuticals and has been involved in COVID-19 vaccine manufacturing agreements. Listed on Indian stock exchanges.

PannonPharma Ltd

Hungary

PannonPharma Ltd is a Hungarian pharmaceutical company based in Pecsvarad, manufacturing pharmaceuticals since 1995. The company produces solid dosage forms (tablets, film-coated tablets, hard gelatin capsules, modified-release tablets), as well as topical products (gels, sprays) and inhalation drops. Products include Diapulmon inhalation drops, Phlogosol antiseptic solution, Ebrimycin antibiotic gel, IRIX spray, and Thaleum allergy eye drops/nasal spray. Offers contract manufacturing services alongside its own product portfolio. GMP certified.

PCI Pharma Services

Australia

PCI Pharma Services is a global CDMO providing fully integrated drug development, manufacturing, clinical trial services, and commercial packaging solutions. With over 8,000 employees in 38 GMP facilities worldwide, PCI offers services spanning sterile fill-finish, lyophilization, oral solid dose manufacturing, complex formulations, and advanced drug delivery including drug-device combination products.

Pell Tech Healthcare Pvt. Ltd.

India

Pelltech Healthcare is a privately owned WHO-GMP approved Indian pharmaceutical company specializing in the manufacture of conventional and modified-release pellets and finished formulations in capsules and tablets. The company has a dedicated state-of-the-art manufacturing facility focused on pellet-based oral solid dosage forms, taking APIs through formulation development to commercial production.

PENMIX Co. Ltd.

South Korea

PENMIX is Korea's largest CDMO, fully committed to globalization of the pharmaceutical industry. The company operates dedicated penicillin manufacturing and general injection manufacturing plants with KGMP and FDA registration. PENMIX provides contract manufacturing services for penicillin formulations (tablets, injections) and sterile injectable products including lyophilized vials, liquid vials, ampoules, and pre-filled syringes, with full automation lines conforming to PICS GMP guidelines.

Pen Tsao Chemical Industry Ltd

China

Pen Tsao Chemical Industry Ltd is a back-integrated manufacturer of APIs, advanced pharma intermediates, and oral solid dosage formulations based in Shanghai, China with over 25 years of experience. The company produces 30+ APIs and formulations from two facilities: a multipurpose plant in Baoshan (56 m3 reactor volume, 218 m3 at Jinshan) and a new site in Pinghu with 270 tons API capacity and 70 tons OSD capacity. Pen Tsao was the first WHO pre-qualified supplier of MDR-tuberculosis drugs.

Pfizer CentreOne

Belgium

Pfizer CentreOne is a global CDMO embedded within Pfizer, specializing in commercial manufacturing of oral solid doses, sterile injectables, biologics including monoclonal antibodies, and antibody-drug conjugates. It leverages Pfizer's global manufacturing network across six continents with cGMP-compliant sites and over 170 years of pharmaceutical manufacturing expertise, backed by $1B+ annual manufacturing investments.

Pharco Corporation

Egypt

Pharco Corporation is the largest pharmaceutical manufacturer in Egypt and the MENA region, comprising 11 companies focused on development, manufacturing, marketing, and distribution of generics and branded generics. The company produces 2.5 million packs daily, exports to 50+ countries, and operates an API manufacturing subsidiary (PBIC) with custom synthesis contracts. Pharco is WHO-prequalified for HCV medicines.

Pharma 5

Morocco

Pharma 5 is a Moroccan pharmaceutical company specializing in the development, manufacturing, and commercialization of pharmaceutical products. The company is the first supplier of tuberculosis treatments in Morocco and developed the first Moroccan anti-Hepatitis C medication. It operates a Smart Factory and holds ISO 9001 certification and Saudi FDA homologation.

Pharmaniaga Manufacturing Berhad

Malaysia

Pharmaniaga Manufacturing Berhad is a Malaysian pharmaceutical manufacturer and CDMO offering contract manufacturing services. The company produces oral solid dosages (7 billion tablets/capsules capacity), liquids (2.9 million bottles), creams (5 million tubes), small volume injectables including ampoules/vials (43 million units), pre-filled syringes and insulin cartridges (25 million units each), and dry syrups. Products include general pharmaceuticals, penicillin, cephalosporin, and OTC products. Facilities are designed to international pharmaceutical engineering guidelines.

Pharmaron

China

Pharmaron is a premier life science CRO/CDMO providing comprehensive R&D and manufacturing services across the entire drug discovery to commercialization process. The company serves small molecules, biologics, ADCs, cell & gene therapies, and protein degraders. It offers laboratory services, chemistry/manufacturing/controls (CMC), clinical development, and biologics/CGT manufacturing. Pharmaron acquired a commercial API manufacturing facility in the UK and operates a gene therapy CDMO in Liverpool with a 20-year track record. The company has over 20 years of experience across 7+ facilities in the UK, US, and China.

Pharmascience

Canada

Pharmascience is Canada's largest privately-owned pharmaceutical company, a leading manufacturer of generic, branded, and over-the-counter pharmaceuticals. The company has recently expanded its CDMO services with a new commercial business unit, investing over $120 million to expand its sterile injectable manufacturing facility in Candiac, Quebec, aiming to more than triple capacity. Pharmascience's ambition is to become a world leader in the sterile injectable CDMO segment. The company distributes products in over 50 countries and invests approximately $65 million per year in R&D in Canada. The Pendopharm division offers specialty medicines in gastroenterology, orthopedics, and neurology.

Pharma Tech Industries

United States

Pharma Tech Industries (PTI) is a pharmaceutical CDMO specializing exclusively in non-sterile dry powder blending and high-speed packaging. Founded in 1972, the company operates multiple FDA-registered, NSF-compliant, climate-controlled facilities in Georgia and Missouri under strict cGMP standards. PTI provides development to high-volume commercial-scale production for pharmaceutical, OTC drug & personal care, and nutritional health & medical foods. Delivery formats include sachets, stick packs, bottles, pouches, effervescents, tablets, capsules, drug-devices, and medical swabs. The company has onsite GMP analytical/microbiology labs and uses quality systems including Empower, eQMS, EDMS, and ERP Serialization. PTI earned the highest possible score in the 2024 CDP SME environmental evaluation.

Pharmathen

Greece

Pharmathen is a Greek research-centred CDMO specializing in complex drug delivery and formulation development. Founded in 1969 and acquired by Partners Group for $1.89 billion, the company operates two state-of-the-art manufacturing facilities: Rodopi (FDA-approved, 15,300 m2, capacity 3.3 billion tablets, 1.2 billion capsules, 175 million blisters, 4 million sterile syringes/vials) and Pallini/Attica (4,000 m2, 800 million tablets/capsules, 1.5 million sterile vials, 6 million ampoules). Pharmathen has also acquired CBL Patras. Key technology platforms include Long Acting Injectables (biodegradable microparticles, nanosuspensions, self-assembled nanogel systems), modified release oral formulations, preservative-free ophthalmic formulations, and solubility/permeability enhancement technologies.

Pharmazeutische Fabrik Montavit GmbH

Austria

Pharmazeutische Fabrik Montavit GmbH is an Austrian family-owned pharmaceutical company founded in 1945 in Absam, Tyrol. The company researches, develops, and manufactures pharmaceutical products and medical devices, exporting to over 80 countries. Montavit offers contract manufacturing (Lohnherstellung/Auftragsfertigung) services to other pharmaceutical companies. Dosage forms include tablets, film-coated tablets, dragees, liquids, creams/gels, granulates, suppositories, sterile pre-filled syringes, laminate tubes, sterile blisters, and powders. The company's own product portfolio covers urology, gynecology, allergy, sleep, travel health, and herbal medicines, with the wound care product Acerbine being well-known.

Phlow Corporation

United States

Phlow Corporation is a U.S.-based public-benefit pharmaceutical manufacturer specializing in onshore continuous-flow production of medicines and APIs. The company was awarded a landmark $354 million HHS/ASPR/BARDA contract to manufacture essential medicines in shortage, strengthening America's pharmaceutical supply chain. Phlow has raised $37 million in Series C funding to expand U.S.-based CDMO operations. The company partners with Fresenius Kabi for the first-ever end-to-end U.S. manufacturing of Epinephrine Injection USP, with Antheia for advanced manufacturing technologies, and with USP for pharmaceutical continuous manufacturing. Phlow is driving sustainable cost competitiveness through advanced manufacturing technology including continuous flow chemistry and AI-enhanced analytics.

Pierre Fabre (CDMO)

France

Pierre Fabre CDMO is the contract development and manufacturing arm of the Pierre Fabre Group, a French pharmaceutical and dermo-cosmetics company. Offers over 20 years of CDMO services across pharma and non-pharma active ingredients, dry forms, non-sterile liquids, and biologics including monoclonal antibodies and ADCs. Operates R&D site in Toulouse and 3+ industrial sites in France. Expertise spans extraction, chromatographic purification, chemical synthesis, cytotoxic compound production, plant cell culture, and supercritical CO2 technology. Manufactures 2,100 metric tons of plant extracts and 100+ active ingredients annually.

Pillar5 Pharma Inc.

Canada

Pillar5 Pharma is a Canadian CDMO founded in 2009, specializing in sterile ophthalmic manufacturing and solid dose production. Market leader in Multi-Dose Preservative Free (MDPF) technology in North America. Produces 30 million ophthalmic bottles and 255 million solid dose tablets per year with 210+ employees. Acquired by ANJAC Sante & Beaute and is also a Prestige Consumer Healthcare company. Health Canada approved, holds FDA Drug Establishment Registration. Acquired former Pfizer site in Arnprior, Ontario.

Pinnacle Life Science

India

Pinnacle Life Science is a subsidiary of the Aarti Group, founded in 2015, offering pharmaceutical manufacturing and CDMO services. Operates a state-of-the-art US FDA-approved manufacturing plant in Baddi, India. Produces 3 billion tablet units, 300 million capsule units, and 100 million oncology OSD units annually. Supplies products to 150+ partners in 90+ countries. Therapeutic focus on oncology, cardiovascular, anti-infective, and diabetic segments with 80+ finished products.

Polpharma / Polpharma API

Kazakhstan

Polpharma is the leader of the Polish pharmaceutical market and one of the leading drug manufacturers in Central and Eastern Europe, with origins dating to 1935. Produces 400 million packages annually across 5 manufacturing plants and 3 R&D centers. The group includes Polpharma API (CDMO/API manufacturing), Polpharma Biologics (state-of-the-art biologic manufacturing including biosimilars and innovative molecules), and Farmaprojects (B2B hub). Has received grants for RNA-based medicines development under the STEP initiative. FDA registered for API manufacture.

Porton Pharma Solutions

China

Porton Pharma Solutions is a global CDMO headquartered in China with over 4,300 employees and operations in the US, Europe (Slovenia), and China. They offer end-to-end services across small molecules, tides (peptides/oligonucleotides), biologics and conjugates (ADCs), and advanced therapy medicinal products. Technical solutions include crystallization, bio catalysis, metal catalysis, flow chemistry, preparative chromatography, milling, and chemical engineering. FDA-registered with 4 FEI numbers for API manufacture, they have 3 FDA inspections with clean outcomes (1 NAI, 2 VAI).

Prahem Laboratories LLP

India

Prahem Laboratories LLP is an Indian pharmaceutical company and sister company of Sneha Medicare Pvt Ltd (established 1985). Based in Mumbai, they operate as a CMO/CDMO with capabilities in development, production, and marketing of specialty medicines, generic medicines, OTC products, and new therapeutic development. Listed on CPHI Online as CMO/CDMO with distributor/import-export and generics/biosimilars manufacturing capabilities. Their business verticals include APIs, finished dosage forms (including oncology and contrast media), and export to LATAM, CIS, and Southeast Asian markets.

Prasfarma

Spain

Prasfarma is a Spanish pharmaceutical company operating as a CMO and CDMO, headquartered in Cerdanyola del Valles (Barcelona) with a manufacturing plant in Manlleu (Barcelona). They are recognized as a reference in the sector for production of oncology (cytostatic) and high potency products. Their product range includes cytostatic oral forms (hard capsules, sachets, film coated and sugar coated tablets), non-cytostatic parenteral forms (vials, ampoules, prefilled syringes), and cytostatic parenteral forms (liquids, lyophilized). Services encompass development, co-development, regulatory affairs, clinical research, production, logistics, and marketing agreements. ISO 14001:2015 certified.

Prime Pharmaceuticals Pvt Ltd.

India

Prime Pharmaceuticals Pvt Ltd. (also known as PRIME PHARMACEUTICALS PVT. LTD) is an Indian R&D-driven CMO and CDMO with significant manufacturing capabilities. IMPORTANT NOTE: The website at primepharmaceuticals.in appears to be a different entity -- an ayurvedic/herbal product brand based in Hissar, India. The actual PRIME PHARMACEUTICALS PVT. LTD. on PharmaSource is a contract manufacturer with FDA-registered facilities (3 FEI numbers), 7 FDA inspections (1 NAI, 6 VAI), 4 Class I recalls, clinical trials in cardiovascular/oncology/ophthalmology, and 3 FDA-approved products (cream, spray, tablet via oral and topical routes). They are listed on CPHI for biosimilars, injectables, and contract manufacturing, and appear at CPHI Frankfurt.

ProMed Pharma

United States

ProMed Pharma is a US-based CDMO specializing in long-acting injectable and implantable dosage forms with nearly 20 years of operational history. The company has mastered polymer-based drug delivery including molding, extrusion, and microencapsulation techniques using silicones, thermoplastics, and biodegradable excipients. ProMed supports projects from early-stage feasibility through commercial manufacturing and has expanded with the acquisition of a 28,000 sq ft facility in Plymouth, Minnesota.

Purna Pharmaceuticals NV

Belgium

Purna Pharmaceuticals NV is an independent Belgian company established in 1986, specializing in contract development and manufacturing of semi-solid (creams, gels, ointments, pastes), liquid, and powder pharmaceutical products. The company has over 30 years of experience and is a preferred contract manufacturing partner for most of the top-10 pharma multinationals. Purna was recently acquired by Ampersand Capital Partners. Manufacturing capabilities include liquids (150L to 10,000L), semi-solids (20L to 2,000L), and powders (10kg to 250kg) with serialization and track-and-trace compliance.

Pyramid Laboratories

United States

Pyramid Laboratories (now Pyramid Pharma Services) is a California-based CDMO established in 1988, specializing in aseptic manufacturing, development, and analytical services for parenteral drugs. The company supports biologics, peptide, and small molecule drugs from pre-clinical development through commercial supply. Pyramid operates a 90,000 sq ft GMP-compliant facility in Costa Mesa, California, and has received investment from Audax Private Equity.

Rivopharm SA

Switzerland

Rivopharm SA is a Swiss-based pharmaceutical company focused on the development, manufacture, and marketing of generic pharmaceutical products at a global level. Founded in 1961 and headquartered in Manno (Lugano), the company offers a portfolio of over 100 molecules with more than 2,000 SKUs across a wide range of therapeutic areas. Rivopharm operates internationally through subsidiaries in the UK, Germany, and the Baltics, and has 87 FDF dossiers and 4 FDA registrations.

Sava Healthcare Ltd

India

SAVA Healthcare Ltd is an Indian pharmaceutical company established in 2003, headquartered in Pune with a WHO-GMP and PIC/s approved manufacturing facility in Surendranagar, Gujarat. The company offers CDMO/CRAMS services and is a leading manufacturer of nasal drug delivery platforms, producing nasal sprays and drops, dry powder inhalers, oral solid doses, and topical preparations.

ScinoPharm (scinopharm.com)

China

ScinoPharm Taiwan is a CDMO headquartered in Tainan Science Park, Taiwan, specializing in high-tech oncology APIs, peptide synthesis, and sterile injectable drug products. With FDA-approved facilities and 18 flexible manufacturing lines, ScinoPharm provides end-to-end services from API development through sterile injectable fill/finish, with a strong focus on complex generics and oncology therapeutics.

Senores Group

India

Senores Group (Senores Pharmaceuticals Limited) is an India-based CDMO specializing in complex generic oral solid dosage forms and API manufacturing. The company operates 5 manufacturing facilities including 2 USFDA-approved formulation plants (Atlanta, USA and Gujarat, India) and 2 API/intermediates plants. Senores serves 300+ customers in 49 countries, with particular strength in controlled substances (C2-C5), extended-release, and orally disintegrating tablet formulations.

Sentiss Pharma Pvt. Ltd.

India

Sentiss Pharma Pvt. Ltd. is an India-based pharmaceutical company specializing in ophthalmic, inhalation (nebulization), otic, and nasal drops, with contract manufacturing capabilities. The company operates sterile manufacturing lines including BFS (Blow-Fill-Seal) technology for eye drops and sterile liquid filling. Sentiss has FDA-registered facilities and has been the first Indian company to introduce eye drops in the Russian market using BFS technology.

Serumwerk Bernburg AG

Germany

Serumwerk Bernburg AG is a medium-sized German pharmaceutical company with over 60 years of tradition in the development and production of medicines, medical devices, and APIs. The company offers APIs and contract manufacturing (Lohnproduktion) services, manufactures sterile infusion and rinsing solutions for hospitals and dialysis centers, ophthalmic products, veterinary medicines, wound care products, and specialty biopolymer-based formulations. Serumwerk has FDA-registered API manufacturing and exports to partners in 60+ countries.

Servier (Servier CDMO)

France

Servier CDMO is the contract manufacturing arm within the global pharmaceutical company Servier, bringing 60 years of expertise in drug product manufacturing and packaging. With 9 manufacturing sites and 16 locations globally, Servier CMO offers services from development through commercial-scale production of tablets, capsules, and powders, distributing over 450 million boxes annually across 150 countries.

Sever Pharma Solutions

France

Sever Pharma Solutions is a specialized CDMO focused on high-potent and cytotoxic drug products (up to OEB6), polymer-based controlled-release delivery systems (implants, vaginal rings), hot melt extrusion for bioavailability enhancement, and prefilled syringe/autoinjector aseptic fill-finish. With sites in Malmö (Sweden) and Putnam (Connecticut, USA), they offer end-to-end services from formulation development through commercial manufacturing.

Simtra BioPharma Solutions

Germany

Simtra BioPharma Solutions is a global CDMO focused exclusively on sterile injectable drug products. With over 65 years of expertise, Simtra offers formulation development, lyophilization cycle optimization, technology transfer, analytical services, fill/finish operations, specialized containment, and global regulatory support. They handle cytotoxics, highly potent compounds, biologics, vaccines, small molecules, ADCs, and diluents. They have a strategic alliance with MilliporeSigma for ADC manufacturing. The company has transferred 60+ ADC candidates including six commercial products to their German site.

Sofgen Pharmaceuticals

United States

Sofgen Pharmaceuticals, part of Procaps Group, is an integrated softgel CDMO that offers end-to-end solutions in softgel technologies from development through delivery. The company serves pharmaceutical, OTC, and nutraceutical customers, with operations across 13 countries in the Americas and customers in 50+ countries.

SOFIE

United States

SOFIE (formerly SOFIE Biosciences) is a U.S.-based radiopharmaceutical company that develops, manufactures, and distributes PET imaging agents and theranostic radiopharmaceuticals. The company operates 14 network pharmacy sites and a Theranostics Center of Excellence in Totowa, NJ. SOFIE offers contract manufacturing services for radiopharmaceuticals under 21 CFR 211 and 212 cGMP standards.

Standard Chem. & Pharm. Co. Ltd

Taiwan

Standard Chem. & Pharm. Co., Ltd. (SCP), established in 1967 in Taiwan, is a renowned global pharmaceutical manufacturer and CDMO with a strong international presence. Their investor materials and pharma alliance documents explicitly describe them as offering CMO/CDMO services. They have manufacturing plants in Tainan (Plant 1 and Plant 2) and operations in Vietnam, Philippines, Thailand, Samoa, China (Taizhou/Jiangsu and Shanghai). The company has collaborated with major Japanese pharmaceutical companies and offers drug development and innovative drug delivery systems. They are a publicly listed company on the Taiwan stock exchange (Stock Symbol: 1720).

Symbiosis Pharmaceutical Services

United Kingdom

Symbiosis Pharmaceutical Services is a world-class sterile fill-finish CDMO based in Stirling, UK, specializing in the GMP manufacture of liquid and lyophilized biological and small molecule drug products. The company serves clinical trial and commercial scale with FDA-inspected and MHRA-licensed facilities. Symbiosis has manufactured its first 10,000-vial commercial batch for a cancer immunotherapy currently in Phase III trials. The company handles a full range of biologics including ATMPs, viral vectors, mAbs, ADCs, RNA/peptide therapies, and vaccines.

Symeres

Netherlands

Symeres is a leading mid-sized transatlantic Contract Research, Development and Manufacturing Organization (CRDMO) providing integrated drug discovery and development services from idea to IND. With 600+ scientists across 9 global sites in Europe and North America, the company combines medicinal chemistry, ADME-tox, biology, formulation development, analytical services, and GMP manufacturing up to 1,000 L scale. The company recently acquired DGr Pharma and Exemplify BioPharma to expand its CMC capabilities.

Syngene International

India

Syngene International is a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO) that provides integrated services spanning drug discovery through commercial manufacturing for both small and large molecules. The company has long-term research collaborations with Bristol Myers Squibb (extended until 2035) and Amgen. Syngene recently opened its first US manufacturing facility in Rockville, Maryland, and added a bioconjugation suite in Bengaluru for end-to-end ADC development. The company has 20 kL single-use drug substance capacity for biologics.

Sypharma Pty Ltd

Australia

Sypharma is an Australian specialty contract manufacturing group operating since 2005. They develop and manufacture therapeutic goods, veterinary products, and specialty consumer products. They specialize in contract manufacturing for early clinical through Phase III clinical trials and have multipurpose cleanrooms for oral, topical, and parenteral drug products. They manufacture both large and small volume parenterals and have a veterinary manufacturing suite. Licensed by FDA, TGA, and ISO 13485 certified. They partnered with Schott on sterile fill/finish capabilities.

Theon Pharmaceuticals Ltd.

India

Indian pharmaceutical contract manufacturer (third-party manufacturer) based in Baddi, Himachal Pradesh. WHO-GMP and ISO 9001:2008 certified. Specializes in manufacturing tablets, capsules, dry syrups, and injectables. Ranked among top 10 leading injectable companies. Launched new state-of-the-art injectable and ophthalmic formulations facility in October 2024 for regulated markets. Has multiple production sections: General, Beta Lactam, Cephalosporins, Dry Powder Injectable. Exports to Africa, South East Asia, CIS, Latin America, and Asia Pacific. Has 12 FDA-approved products including injectables and oral tablets.

Thépenier Pharma & Cosmetics

France

French CDMO and OEM-ODM with over 60 years of experience, specializing in development and manufacturing of pharmaceutical, skincare, personal care, and makeup products. Part of an international group with French-Japanese DNA (parent company is Japanese cosmetics manufacturer). All products manufactured in GMP-compliant environment. Pharmaceutical specialization in dermatological products and ENT (ear, nose, throat) sphere products. Revenue of 117M USD (40% export), 850 employees, 70 R&I researchers, 60 engineers/pharmacists. Facilities in Normandy (2 sites) and Orleans, France.

The Ritedose Corporation

United States

The largest US CDMO specializing in sterile Blow-Fill-Seal (BFS) technology for aseptic manufacturing of unit-dose medications. Based in Columbia, South Carolina with a 500,000+ sq ft facility and production capacity of over 2.6 billion units annually. Delivered more than 12 billion doses since 2012 with no patient interruptions. Provides both CDMO services and has a generics division. Offers the largest nebulized drug portfolio in the US. Key products include ophthalmic, respiratory, and inhalation medications. Has co-developed 80%+ of new BFS products over the past decade. 100% customer retention for 25 years. Recent investments include $17M cGMP lab expansion and seventh Syntegon packaging line. 16 FDA-approved products.

Thermo Fisher Scientific Inc.

China

One of the world's largest pharmaceutical CDMOs through its Patheon pharma services division. Provides end-to-end pharmaceutical development and manufacturing services for both small molecules and biologics, from API manufacturing through drug product, sterile fill/finish, packaging, and commercial supply. Operates 31+ FDA-registered facilities globally. 158 FDA inspections on record (52 NAI, 104 VAI, 2 OAI). Also provides cell therapy manufacturing solutions (CTS Rotea cell processing system), laboratory informatics, bioprocessing equipment, and reagents. 4 FDA-approved drug products. Revenue >$40B (full company).